Showing results (161-170 of 194) with videos related to
Sort By:
Pageof 20
Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.Nature Communications|May 20, 2020
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.Nature Communications|March 21, 2020
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancerAnniina Färkkilä, Doga C Gulhan, Julia Casado, et al.Gynecologic Oncology|August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinomaNicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.JAMA Oncology|June 14, 2019
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian CarcinomaPanagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2022
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984Joseph W Kim, Rana R McKay, Marc R Radke, et al.Gynecologic Oncology|September 9, 2017
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2Amit M Oza, Anna V Tinker, Ana Oaknin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2022
Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-AnalysisMiranda P Steenbeek, Majke H D van Bommel, Johan Bulten, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian CarcinomaAmit M Oza, Domenica Lorusso, Carol Aghajanian, et al.Cancer Discovery|November 15, 2018
<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaKevin K Lin, Maria I Harrell, Amit M Oza, et al.Pageof 20